Phase III Keytruda + Lenvima study shows improved OS, PFS in advanced endometrial cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A combination of Keytruda (pembrolizumab) and Lenvima (lenvatinib) demonstrated statistically significant improvement in overall survival, progression-free survival and objective response rate versus chemotherapy in patients with advanced endometrial cancer.

Keytruda is sponsored by Merck, and Lenvima is sponsored by Eisai.

The phase III KEYNOTE-775/Study 309 trial evaluating the investigational use of Keytruda, an anti-PD-1 therapy, plus Lenvima, the orally available multiple receptor tyrosine kinase inhibitor, met its dual primary endpoints of OS and PFS, and its secondary efficacy endpoint of ORR in patients with advanced endometrial cancer following at least one prior platinum-based regimen.

These positive results were observed in the mismatch repair proficient subgroup and the intention-to-treat study population, which includes both patients with endometrial carcinoma that is pMMR as well as patients whose disease is microsatellite instability-high (MSI-H)/mismatch repair deficient.

Based on an analysis conducted by an independent data monitoring committee, Keytruda plus Lenvima demonstrated a statistically significant and clinically meaningful improvement in OS, PFS and ORR versus chemotherapy (treatment of physician’s choice [TPC] of doxorubicin or paclitaxel).

The safety profile of the Keytruda plus Lenvima combination was consistent with previously reported studies. Merck and Eisai will discuss these data with regulatory authorities worldwide, with the intent to submit marketing authorization applications based on these results, and plan to present these results at an upcoming medical meeting.

KEYNOTE-775/Study 309 is the confirmatory trial for KEYNOTE-146/Study 111, which supported FDA’s 2019 accelerated approval of the Keytruda plus Lenvima combination for the treatment of patients with advanced endometrial carcinoma that is not MSI-H or dMMR, who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation.

This accelerated approval was based on tumor response rate and durability of response and was the first approval granted under Project Orbis. Under Project Orbis, Health Canada and Australia’s Therapeutic Goods Administration granted conditional and provisional approvals, respectively, for this indication.

Merck and Eisai are studying the Keytruda plus Lenvima combination through the LEAP (LEnvatinib And Pembrolizumab) clinical program in 13 different tumor types across 20 clinical trials, including a phase III trial evaluating the combination in the first-line setting for patients with advanced endometrial carcinoma (LEAP-001).

Table of Contents

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login